Details

Autor(en) / Beteiligte

• Zhang, Tao
• Lu, Mingjian
• Peng, Sheng
• Zhang, Weidong
• Yang, Guang
• Liu, Zhenyin
• Singh, Sristi
• Yang, Yadi
• Zhang, Fujun
• Gao, Fei

Titel

CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy

Ist Teil von

• Journal of cancer research and clinical oncology, 2014-08, Vol.140 (8), p.1383-1390

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose We investigated implanting computed tomography (CT)-guided 125 I seed to treat locally advanced non-small-cell lung cancer (NSCLC) after chemotherapy failure. Methods From January 2005 to July 2010, we recruited 69 patients with locally advanced NSCLC who had each had first-line chemotherapy four to six times but had progressive disease; 34 received 125 I seed implantation with second-line chemotherapy (Group A) and 35 received second-line chemotherapy only (Group B). Results Mean follow-up was 32 months (range 5–56 months). Overall 2-year local control rate for existing lung lesions was Group A: 39.9 %; Group B: 12.5 % ( P  < 0.05). The 1-, 3-year, and median overall survival was 68.7 and 20.8 % at 17.4 months in Group A; and 45.1 and 18.7 % at 11.3 months in Group B, respectively ( P  > 0.05). Local 3-, 24-month, and median progression-free survival was Group A: 100 and 79.1 % at 11 months; Group B: 76.5 and 18.7 % at 7.3 months, respectively. The groups did not significantly differ in treatment toxicity. Chest pain remission was Group A: 82.1 % (23/28); Group B: 30.8 % (8/26) ( P  < 0.05). Group A showed no radiation-related pneumonia, esophagitis, bronchial fistulae, or life-threatening morbidity. Conclusion CT-guided radioactive seed 125 I implantation procedure is safe and well tolerated in treating locally advanced NSCLC, with few complications. It has good local control rate and can relieve symptoms without increasing side effects.